Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?

insidermonkey.com · 2026-09-09

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune ...

TickrTrends take: Bristol-Myers Squibb faces headwinds from broader CAR-T safety concerns affecting the Healthcare sector, yet TickrTrends currently rates the stock as Overvalued based on its derived metrics. Investors focused on valuation should monitor whether sector-wide safety issues further pressure BMY's pricing power or if the company can differentiate its CAR-T portfolio to justify current valuations. The competitive dynamics with peers like Novartis will be critical in determining whether BMY can narrow the valuation gap that TickrTrends has identified.

Read the full story at insidermonkey.com →